To read the full story, subscribe or sign in.

Samsung Bioepis wins nod for Korea’s first Stelara biosimilar

April 12, 2024

Samsung Bioepis Co. Ltd., of Incheon, South Korea, is the latest to announce a win in the biosimilar space, gaining MFDS approval of Epyztek (SB-17) as the country’s first biosimilar to Stelara (ustekinumab, Janssen Pharmaceutical Inc.) on April 11.

BioWorld Asia Regulatory Inflammatory Biosimilar Asia-Pacific MOHW

Today's news in brief

BioWorld

BioWorld briefs for Dec. 30, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 30, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Cell mapping yields clues to metabolic health in obese individuals

BioWorld

Researchers at the University of Leipzig and ETH Zurich have used single-cell sequencing to identify differences between fat tissue of obese individuals who are...